We are live on
!
Find out more
BVF Inc Portfolio holdings
AUM
$3.91B
Turnover
15.22%
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter
Est. Return
+38.64%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.54B
AUM Growth
+$706M
(+38%)
Cap. Flow
+$104M
Cap. Flow
% of AUM
4.08%
Top 10 Holdings %
Top 10 Hldgs %
54.04%
Holding
74
New
12
Increased
16
Reduced
23
Closed
6
Avg Time Held
1.7
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Olema Pharmaceuticals
OLMA
|
+$312M |
| 2 |
Amarin Corp
AMRN
|
+$46.6M |
| 3 |
4D Molecular Therapeutics
FDMT
|
+$45.7M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$40.9M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$31.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpringWorks Therapeutics
SWTX
|
+$132M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$87.3M |
| 3 |
Celldex Therapeutics
CLDX
|
+$45.5M |
| 4 |
Replimune Group
REPL
|
+$38.9M |
| 5 |
Xencor
XNCR
|
+$33.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.26% |
| 2 | Miscellaneous | 0.42% |
| 3 | Financials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
PHXM
51
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
| $6.12M | 0.24% |
62,500
| – | – |
2017 Q4
12 quarters
|
|
52
Eocene Ltd. Ordinary Shares
EOCN
$3.26M
| $5.6M | 0.22% |
1,250
| – | – |
2018 Q2
10 quarters
|
|
|
EUCRU
53
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
| $5.33M | 0.21% |
+500,000
| New | +$5.08M |
2020 Q4
0 quarters
|
|
|
FLACU
54
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
| $5.21M | 0.2% |
+500,000
| New | +$5.22M |
2020 Q4
0 quarters
|
|
55
Curis
CRIS
$1.23M
| $5.13M | 0.2% |
1,567
-7,558
| -83% | -$9.08M |
2020 Q2
2 quarters
|
|
56
X4 Pharmaceuticals
XFOR
$262M
| $5.1M | 0.2% |
26,430
| – | – |
2019 Q2
6 quarters
|
|
|
FVAM
57
DELISTED
5:01 Acquisition Corp
FVAM
| $5.08M | 0.2% |
+500,000
| New | +$5.05M |
2020 Q4
0 quarters
|
|
58
Phathom Pharmaceuticals
PHAT
$607M
| $5.01M | 0.2% |
150,787
-171,311
| -53% | -$6.94M |
2019 Q4
4 quarters
|
|
59
DELISTED
Regulus Therapeutics
RGLS
| $4.56M | 0.18% |
337,621
+15,873
| +5% | +$117K |
2017 Q1
15 quarters
|
|
|
FWP
60
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $4.56M | 0.18% |
647,299
| – | – |
2014 Q4
24 quarters
|
|
61
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $3.44M | 0.14% |
493,517
| – | – |
2015 Q3
21 quarters
|
|
|
JYAC
62
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $3.09M | 0.12% |
+300,000
| New | +$3.05M |
2020 Q4
0 quarters
|
|
63
Rezolute
RZLT
$377M
| $2.36M | 0.09% |
+190,814
| New | +$3.54M |
2020 Q4
0 quarters
|
|
|
SNCE
64
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $1.06M | 0.04% |
+5,000
| New | +$1.04M |
2020 Q4
0 quarters
|
|
|
FSTX
65
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $255K | 0.01% |
25,844
-209,449
| -89% | -$1.37M |
2017 Q2
14 quarters
|
|
66
Viridian Therapeutics
VRDN
$2.22B
| $160K | 0.01% |
+9,747
| New | +$147K |
2020 Q4
0 quarters
|
|
|
PANA.U
67
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
| $126K | 0.01% |
9,837
-790,163
| -99% | -$8.72M |
2020 Q3
1 quarter
|
|
|
68
DELISTED
SpringWorks Therapeutics
SWTX
| $4K | ﹤0.01% |
50
-2,053,941
| -100% | -$132M |
2019 Q3
5 quarters
|
|
69
AnaptysBio
ANAB
$1.46B
| – | – |
-1,227,405
| Closed | -$18.1M | – |
|
70
BioLineRX
BLRX
$10.2M
| – | – |
-42,159
| Closed | -$2.77M | – |
|
|
71
Celldex Therapeutics
CLDX
$2.27B
| – | – |
-3,066,797
| Closed | -$45.5M | – |
|
72
Exelixis
EXEL
$15.6B
| – | – |
-15,300
| Closed | -$374K | – |
|
|
73
Replimune Group
REPL
$1.11B
| – | – |
-1,691,834
| Closed | -$38.9M | – |
|
|
EVLO
74
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| – | – |
-65,000
| Closed | -$6.85M | – |
|
Similar funds
LFCM
DCM
AC
BVF Inc's Q4 2020 Portfolio in Review
As of Q4 2020, BVF Inc held 74 positions worth $2.54B, up 38% from $1.84B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
BVF Inc deployed $104M of net new capital in Q4 2020, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Olema Pharmaceuticals: 6,661,503 shares worth $320M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $132M trimmed.
- BVF Inc's largest Q4 2020 buy was Olema Pharmaceuticals: 6,661,503 shares worth $320M.
- BVF Inc added most to Amarin Corp in Q4 2020, an estimated $46.6M increase.
- BVF Inc's biggest Q4 2020 reduction was SpringWorks Therapeutics, cutting an estimated $132M.
- BVF Inc fully exited Celldex Therapeutics in Q4 2020, selling an estimated $45.5M.
- BVF Inc's ten largest holdings make up 54% of its $2.54B portfolio in Q4 2020.
- BVF Inc opened 12 new positions and closed 6 in Q4 2020.
- BVF Inc's portfolio value rose 38% quarter-over-quarter to $2.54B.
Based on BVF Inc's 13F filing for Q4 2020, filed 12 Feb 2021.